Jennifer Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer Ma has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Andrew Bell
10 shared publicationsQiang Li
9 shared publicationsDean Bajorin
8 shared publications- Nadeem Riaz
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
8 shared publications Alexis W. Damish
7 shared publicationsAtanas Kamburov
7 shared publications
Latest Publications
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
Purpose:The importance of the DNA damage response in mediating effects of radiotherapy (RT) has galvanized efforts to target this pathway with radiosensitizers. Yet early clinical trials of this approach have failed to yield a benefit in unselected populations. We hypothesized that ataxia–telangiectasia mutated (Atm)–null tumors would demonstrate genotype-specific synergy between RT and an inhibitor of the DNA damage response protein ataxia–telangiectasia and Rad3-related (ATR) kinase.Experimental Design:We investigated the synergistic potential of the ATR inhibitor (ATRi) RP-3500 and RT in two Atm-null and isogenic murine models, both in vitro and in vivo. Staining of γ-H2AX foci, characterization of the immune response via flow cytometry, and tumor rechallenge experiments were performed to elucidate the mechanism of interaction. To examine genotype specificity, we tested the interaction of ATRi and RT in a Brca1-null model. Finally, patients with advanced cancer with ATM alterations were enrolled in a phase I/II clinical trial to validate preclinical findings.Results:Synergy between RP-3500 and RT was confirmed in Atm-null lines in vitro, characterized by an accumulation of DNA double-strand breaks. In vivo, Atm-null tumor models had higher rates of durable control with RT and ATRi than controls. In contrast, there was no synergy in tumors lacking Brca1. Analysis of the immunologic response indicated that efficacy is largely mediated by cell-intrinsic mechanisms. Lastly, early results from our clinical trial showed complete responses in patients.Conclusions:Genotype-directed radiosensitization with ATRi and RT can unleash significant therapeutic benefit and could represent a novel approach to develop more effective combinatorial synthetic cytotoxic RT-based treatments.See related commentary by Schrank and Colbert, p. 5505
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
Purpose:The importance of the DNA damage response in mediating effects of radiotherapy (RT) has galvanized efforts to target this pathway with radiosensitizers. Yet early clinical trials of this approach have failed to yield a benefit in unselected populations. We hypothesized that ataxia–telangiectasia mutated (Atm)–null tumors would demonstrate genotype-specific synergy between RT and an inhibitor of the DNA damage response protein ataxia–telangiectasia and Rad3-related (ATR) kinase.Experimental Design:We investigated the synergistic potential of the ATR inhibitor (ATRi) RP-3500 and RT in two Atm-null and isogenic murine models, both in vitro and in vivo. Staining of γ-H2AX foci, characterization of the immune response via flow cytometry, and tumor rechallenge experiments were performed to elucidate the mechanism of interaction. To examine genotype specificity, we tested the interaction of ATRi and RT in a Brca1-null model. Finally, patients with advanced cancer with ATM alterations were enrolled in a phase I/II clinical trial to validate preclinical findings.Results:Synergy between RP-3500 and RT was confirmed in Atm-null lines in vitro, characterized by an accumulation of DNA double-strand breaks. In vivo, Atm-null tumor models had higher rates of durable control with RT and ATRi than controls. In contrast, there was no synergy in tumors lacking Brca1. Analysis of the immunologic response indicated that efficacy is largely mediated by cell-intrinsic mechanisms. Lastly, early results from our clinical trial showed complete responses in patients.Conclusions:Genotype-directed radiosensitization with ATRi and RT can unleash significant therapeutic benefit and could represent a novel approach to develop more effective combinatorial synthetic cytotoxic RT-based treatments.See related commentary by Schrank and Colbert, p. 5505
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 from Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 from Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
- 10 July 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (3) , 768-779
Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors
- 10 July 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (3) , 768-779
Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors
- 9 July 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (24) , 5643-5656
Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
Purpose: The importance of the DNA damage response in mediating effects of radiotherapy (RT) has galvanized efforts to target this pathway with radiosensitizers. Yet early clinical trials of this approach have failed to yield a benefit in unselected populations. We hypothesized that ataxia–telangiectasia mutated (Atm)–null tumors would demonstrate genotype-specific synergy between RT and an inhibitor of the DNA damage response protein ataxia–telangiectasia and Rad3-related (ATR) kinase. Experimental Design: We investigated the synergistic potential of the ATR inhibitor (ATRi) RP-3500 and RT in two Atm-null and isogenic murine models, both in vitro and in vivo. Staining of γ-H2AX foci, characterization of the immune response via flow cytometry, and tumor rechallenge experiments were performed to elucidate the mechanism of interaction. To examine genotype specificity, we tested the interaction of ATRi and RT in a Brca1-null model. Finally, patients with advanced cancer with ATM alterations were enrolled in a phase I/II clinical trial to validate preclinical findings. Results: Synergy between RP-3500 and RT was confirmed in Atm-null lines in vitro, characterized by an accumulation of DNA double-strand breaks. In vivo, Atm-null tumor models had higher rates of durable control with RT and ATRi than controls. In contrast, there was no synergy in tumors lacking Brca1. Analysis of the immunologic response indicated that efficacy is largely mediated by cell-intrinsic mechanisms. Lastly, early results from our clinical trial showed complete responses in patients. Conclusions: Genotype-directed radiosensitization with ATRi and RT can unleash significant therapeutic benefit and could represent a novel approach to develop more effective combinatorial synthetic cytotoxic RT-based treatments. See related commentary by Schrank and Colbert, p. 5505
- 9 July 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (24) , 5643-5656
Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
Purpose: The importance of the DNA damage response in mediating effects of radiotherapy (RT) has galvanized efforts to target this pathway with radiosensitizers. Yet early clinical trials of this approach have failed to yield a benefit in unselected populations. We hypothesized that ataxia–telangiectasia mutated (Atm)–null tumors would demonstrate genotype-specific synergy between RT and an inhibitor of the DNA damage response protein ataxia–telangiectasia and Rad3-related (ATR) kinase. Experimental Design: We investigated the synergistic potential of the ATR inhibitor (ATRi) RP-3500 and RT in two Atm-null and isogenic murine models, both in vitro and in vivo. Staining of γ-H2AX foci, characterization of the immune response via flow cytometry, and tumor rechallenge experiments were performed to elucidate the mechanism of interaction. To examine genotype specificity, we tested the interaction of ATRi and RT in a Brca1-null model. Finally, patients with advanced cancer with ATM alterations were enrolled in a phase I/II clinical trial to validate preclinical findings. Results: Synergy between RP-3500 and RT was confirmed in Atm-null lines in vitro, characterized by an accumulation of DNA double-strand breaks. In vivo, Atm-null tumor models had higher rates of durable control with RT and ATRi than controls. In contrast, there was no synergy in tumors lacking Brca1. Analysis of the immunologic response indicated that efficacy is largely mediated by cell-intrinsic mechanisms. Lastly, early results from our clinical trial showed complete responses in patients. Conclusions: Genotype-directed radiosensitization with ATRi and RT can unleash significant therapeutic benefit and could represent a novel approach to develop more effective combinatorial synthetic cytotoxic RT-based treatments. See related commentary by Schrank and Colbert, p. 5505
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Information from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Supplementary Figures and Methods // Supplementary Figure 1: The DDB2 proteo-probe assay measures cellular nucleotide excision repair (NER) capacity. Low magnification (20X) images of wild-type (WT) or mutant ERCC2-complemented XP cells before, 5 minutes after, and 150 minutes after UV exposure (see Figure 1 for high magnification [63X] images). DDB2 proteoprobe binding to UV-induced (6,4)-photoproducts is visualized using an anti-FLAG antibody (red). Nuclei are stained with DAPI (blue). ERCC2 expression is confirmed with an anti-Myc antibody (green). R683W is a common germline pathogenic allele, D312N is a common non-pathogenic germline allele, and G607A is a mutation identified in a cisplatin responsive tumor. Supplementary Figure 2: Sensitivity profiles for WT and mutant ERCC2-complemented cells for non-cisplatin agents. A. Carboplatin. B. Doxorubicin (Adriamycin) is a DNA intercalating agents that results in creation of double-strand DNA breaks. C. Rucaparib is a poly(ADP-ribose) polymerase inhibitor that demonstrates enhanced toxicity in homologous recombination (HR)-deficient cells. D. Ionizing radiation (IR). R683W is a common pathogenic germline allele in patients with the xeroderma pigmentosum complementation group D (XPD). D312N is a common, non-pathogenic germline ERCC2 allele in the general population. Y14C and G607A are helicase domain mutations identified in cisplatin responsive patients and are associated with NER loss and cisplatin sensitivity (Figure 2). Supplementary Figure 3: ERCC2 mutations identified in cisplatin non-responders are functionally deleterious. A. Cisplatin sensitivity curves for WT or mutant ERCC2-complemented cells. Whereas WT ERCC2 rescues cisplatin sensitivity, the sensitivity profiles for S44L and S246F, identified in two cisplatin non-responders from the FCCC cohort, are similar to mock-infected cells. B. The S44L and S246F mutants also fail to rescue sensitivity to UV sensitivity. C. Immunoblot showing expression of FLAG-tagged WT or mutant ERCC2. Supplementary Figure 4: Identification of an ERCC2 E86Q mutation in matched pre- and post-treatment tumor samples. The E86Q mutation was not identified in the pre-treatment sample by the standard mutation-calling algorithm due to the low number of reads, but was later identified by "force-calling" after the E86Q mutation was identified in the post-treatment sample. Correcting for tumor purity, the E86Q mutation was inferred to be clonal in both the pre- and post-treatment samples. Supplementary Figure 5: Phylogenetic tree showing relationship between pre- and post-chemotherapy tumors from a patient with an ERCC2 E86Q mutation. The pre- and post-chemotherapy tumors share several mutations, indicating a common ancestor. Shared mutations in other select cancer genes are noted. Supplementary Figure 6: CRISPR/Cas9 technology was used to create a KU19-19 cell line harboring an in-frame deletion at the endogenous ERCC2 allele. A. An sgRNA guide was designed to target the region near T484, a common site of ERCC2 mutations in MIBC tumors. B. Integrated Genomics Viewer (IGV) screenshot showing sequence of WT ERCC2 allele in KU19-19 parental cell line. C. The CRISPR-edited cell line KE1 harbors an in-frame deletion at T484. Supplementary Figure 7: An ERCC2 mutation confers an NER defect in a bladder cancer cell line. Low magnification (20X) images from a DDB2 proteoprobe assay comparing KU19-19 (WT ERCC2) and KE1 (mutant ERCC2) cell lines (see Figure 4 for high magnification [63X] images). Whereas the KU19-19 cell line efficiently resolves DDB2 foci, the foci persist in NER-deficient KE1 cells. Supplementary Figure 8: KU19-19 (WT ERCC2) and KE1 (mutant ERCC2) cell lines have similar sensitivity to the PARP inhibitor olaparib. Supplementary Figure 9: Overall survival for patients with ERCC2 wild-type (blue) versus mutant (red) tumors in the updated TCGA bladder tumor cohort (Robertson et al. Cell 2017; 171:1-17). There was no significant difference in survival between the groups (P=0.095). This figure was created using cBioPortal (Gao et al. Sci Signaling 2013; 6(269):pl1 and Cerami et al. Cancer Discov 2012; 2(5):401).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Information from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Supplementary Figures and Methods // Supplementary Figure 1: The DDB2 proteo-probe assay measures cellular nucleotide excision repair (NER) capacity. Low magnification (20X) images of wild-type (WT) or mutant ERCC2-complemented XP cells before, 5 minutes after, and 150 minutes after UV exposure (see Figure 1 for high magnification [63X] images). DDB2 proteoprobe binding to UV-induced (6,4)-photoproducts is visualized using an anti-FLAG antibody (red). Nuclei are stained with DAPI (blue). ERCC2 expression is confirmed with an anti-Myc antibody (green). R683W is a common germline pathogenic allele, D312N is a common non-pathogenic germline allele, and G607A is a mutation identified in a cisplatin responsive tumor. Supplementary Figure 2: Sensitivity profiles for WT and mutant ERCC2-complemented cells for non-cisplatin agents. A. Carboplatin. B. Doxorubicin (Adriamycin) is a DNA intercalating agents that results in creation of double-strand DNA breaks. C. Rucaparib is a poly(ADP-ribose) polymerase inhibitor that demonstrates enhanced toxicity in homologous recombination (HR)-deficient cells. D. Ionizing radiation (IR). R683W is a common pathogenic germline allele in patients with the xeroderma pigmentosum complementation group D (XPD). D312N is a common, non-pathogenic germline ERCC2 allele in the general population. Y14C and G607A are helicase domain mutations identified in cisplatin responsive patients and are associated with NER loss and cisplatin sensitivity (Figure 2). Supplementary Figure 3: ERCC2 mutations identified in cisplatin non-responders are functionally deleterious. A. Cisplatin sensitivity curves for WT or mutant ERCC2-complemented cells. Whereas WT ERCC2 rescues cisplatin sensitivity, the sensitivity profiles for S44L and S246F, identified in two cisplatin non-responders from the FCCC cohort, are similar to mock-infected cells. B. The S44L and S246F mutants also fail to rescue sensitivity to UV sensitivity. C. Immunoblot showing expression of FLAG-tagged WT or mutant ERCC2. Supplementary Figure 4: Identification of an ERCC2 E86Q mutation in matched pre- and post-treatment tumor samples. The E86Q mutation was not identified in the pre-treatment sample by the standard mutation-calling algorithm due to the low number of reads, but was later identified by "force-calling" after the E86Q mutation was identified in the post-treatment sample. Correcting for tumor purity, the E86Q mutation was inferred to be clonal in both the pre- and post-treatment samples. Supplementary Figure 5: Phylogenetic tree showing relationship between pre- and post-chemotherapy tumors from a patient with an ERCC2 E86Q mutation. The pre- and post-chemotherapy tumors share several mutations, indicating a common ancestor. Shared mutations in other select cancer genes are noted. Supplementary Figure 6: CRISPR/Cas9 technology was used to create a KU19-19 cell line harboring an in-frame deletion at the endogenous ERCC2 allele. A. An sgRNA guide was designed to target the region near T484, a common site of ERCC2 mutations in MIBC tumors. B. Integrated Genomics Viewer (IGV) screenshot showing sequence of WT ERCC2 allele in KU19-19 parental cell line. C. The CRISPR-edited cell line KE1 harbors an in-frame deletion at T484. Supplementary Figure 7: An ERCC2 mutation confers an NER defect in a bladder cancer cell line. Low magnification (20X) images from a DDB2 proteoprobe assay comparing KU19-19 (WT ERCC2) and KE1 (mutant ERCC2) cell lines (see Figure 4 for high magnification [63X] images). Whereas the KU19-19 cell line efficiently resolves DDB2 foci, the foci persist in NER-deficient KE1 cells. Supplementary Figure 8: KU19-19 (WT ERCC2) and KE1 (mutant ERCC2) cell lines have similar sensitivity to the PARP inhibitor olaparib. Supplementary Figure 9: Overall survival for patients with ERCC2 wild-type (blue) versus mutant (red) tumors in the updated TCGA bladder tumor cohort (Robertson et al. Cell 2017; 171:1-17). There was no significant difference in survival between the groups (P=0.095). This figure was created using cBioPortal (Gao et al. Sci Signaling 2013; 6(269):pl1 and Cerami et al. Cancer Discov 2012; 2(5):401).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Purpose:DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely among patients. Here, we sought to define the role of the nucleotide excision repair (NER) gene ERCC2 as a biomarker predictive of response to cisplatin in MIBC.Experimental Design:Somatic missense mutations in ERCC2 are associated with improved response to cisplatin-based chemotherapy; however, clinically identified ERCC2 mutations are distributed throughout the gene, and the impact of individual ERCC2 variants on NER capacity and cisplatin sensitivity is unknown. We developed a microscopy-based NER assay to profile ERCC2 mutations observed retrospectively in prior studies and prospectively within the context of an institution-wide tumor profiling initiative. In addition, we created the first ERCC2-deficient bladder cancer preclinical model for studying the impact of ERCC2 loss of function.Results:We used our functional assay to test the NER capacity of clinically observed ERCC2 mutations and found that most ERCC2 helicase domain mutations cannot support NER. Furthermore, we show that introducing an ERCC2 mutation into a bladder cancer cell line abrogates NER activity and is sufficient to drive cisplatin sensitivity in an orthotopic xenograft model.Conclusions:Our data support a direct role for ERCC2 mutations in driving cisplatin response, define the functional landscape of ERCC2 mutations in bladder cancer, and provide an opportunity to apply combined genomic and functional approaches to prospectively guide therapy decisions in bladder cancer.See related commentary by Grivas, p. 907
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Purpose:DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely among patients. Here, we sought to define the role of the nucleotide excision repair (NER) gene ERCC2 as a biomarker predictive of response to cisplatin in MIBC.Experimental Design:Somatic missense mutations in ERCC2 are associated with improved response to cisplatin-based chemotherapy; however, clinically identified ERCC2 mutations are distributed throughout the gene, and the impact of individual ERCC2 variants on NER capacity and cisplatin sensitivity is unknown. We developed a microscopy-based NER assay to profile ERCC2 mutations observed retrospectively in prior studies and prospectively within the context of an institution-wide tumor profiling initiative. In addition, we created the first ERCC2-deficient bladder cancer preclinical model for studying the impact of ERCC2 loss of function.Results:We used our functional assay to test the NER capacity of clinically observed ERCC2 mutations and found that most ERCC2 helicase domain mutations cannot support NER. Furthermore, we show that introducing an ERCC2 mutation into a bladder cancer cell line abrogates NER activity and is sufficient to drive cisplatin sensitivity in an orthotopic xenograft model.Conclusions:Our data support a direct role for ERCC2 mutations in driving cisplatin response, define the functional landscape of ERCC2 mutations in bladder cancer, and provide an opportunity to apply combined genomic and functional approaches to prospectively guide therapy decisions in bladder cancer.See related commentary by Grivas, p. 907
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Purpose:DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely among patients. Here, we sought to define the role of the nucleotide excision repair (NER) gene ERCC2 as a biomarker predictive of response to cisplatin in MIBC.Experimental Design:Somatic missense mutations in ERCC2 are associated with improved response to cisplatin-based chemotherapy; however, clinically identified ERCC2 mutations are distributed throughout the gene, and the impact of individual ERCC2 variants on NER capacity and cisplatin sensitivity is unknown. We developed a microscopy-based NER assay to profile ERCC2 mutations observed retrospectively in prior studies and prospectively within the context of an institution-wide tumor profiling initiative. In addition, we created the first ERCC2-deficient bladder cancer preclinical model for studying the impact of ERCC2 loss of function.Results:We used our functional assay to test the NER capacity of clinically observed ERCC2 mutations and found that most ERCC2 helicase domain mutations cannot support NER. Furthermore, we show that introducing an ERCC2 mutation into a bladder cancer cell line abrogates NER activity and is sufficient to drive cisplatin sensitivity in an orthotopic xenograft model.Conclusions:Our data support a direct role for ERCC2 mutations in driving cisplatin response, define the functional landscape of ERCC2 mutations in bladder cancer, and provide an opportunity to apply combined genomic and functional approaches to prospectively guide therapy decisions in bladder cancer.See related commentary by Grivas, p. 907
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Purpose:DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely among patients. Here, we sought to define the role of the nucleotide excision repair (NER) gene ERCC2 as a biomarker predictive of response to cisplatin in MIBC.Experimental Design:Somatic missense mutations in ERCC2 are associated with improved response to cisplatin-based chemotherapy; however, clinically identified ERCC2 mutations are distributed throughout the gene, and the impact of individual ERCC2 variants on NER capacity and cisplatin sensitivity is unknown. We developed a microscopy-based NER assay to profile ERCC2 mutations observed retrospectively in prior studies and prospectively within the context of an institution-wide tumor profiling initiative. In addition, we created the first ERCC2-deficient bladder cancer preclinical model for studying the impact of ERCC2 loss of function.Results:We used our functional assay to test the NER capacity of clinically observed ERCC2 mutations and found that most ERCC2 helicase domain mutations cannot support NER. Furthermore, we show that introducing an ERCC2 mutation into a bladder cancer cell line abrogates NER activity and is sufficient to drive cisplatin sensitivity in an orthotopic xenograft model.Conclusions:Our data support a direct role for ERCC2 mutations in driving cisplatin response, define the functional landscape of ERCC2 mutations in bladder cancer, and provide an opportunity to apply combined genomic and functional approaches to prospectively guide therapy decisions in bladder cancer.See related commentary by Grivas, p. 907
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Information from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Supplementary Figures and Methods // Supplementary Figure 1: The DDB2 proteo-probe assay measures cellular nucleotide excision repair (NER) capacity. Low magnification (20X) images of wild-type (WT) or mutant ERCC2-complemented XP cells before, 5 minutes after, and 150 minutes after UV exposure (see Figure 1 for high magnification [63X] images). DDB2 proteoprobe binding to UV-induced (6,4)-photoproducts is visualized using an anti-FLAG antibody (red). Nuclei are stained with DAPI (blue). ERCC2 expression is confirmed with an anti-Myc antibody (green). R683W is a common germline pathogenic allele, D312N is a common non-pathogenic germline allele, and G607A is a mutation identified in a cisplatin responsive tumor. Supplementary Figure 2: Sensitivity profiles for WT and mutant ERCC2-complemented cells for non-cisplatin agents. A. Carboplatin. B. Doxorubicin (Adriamycin) is a DNA intercalating agents that results in creation of double-strand DNA breaks. C. Rucaparib is a poly(ADP-ribose) polymerase inhibitor that demonstrates enhanced toxicity in homologous recombination (HR)-deficient cells. D. Ionizing radiation (IR). R683W is a common pathogenic germline allele in patients with the xeroderma pigmentosum complementation group D (XPD). D312N is a common, non-pathogenic germline ERCC2 allele in the general population. Y14C and G607A are helicase domain mutations identified in cisplatin responsive patients and are associated with NER loss and cisplatin sensitivity (Figure 2). Supplementary Figure 3: ERCC2 mutations identified in cisplatin non-responders are functionally deleterious. A. Cisplatin sensitivity curves for WT or mutant ERCC2-complemented cells. Whereas WT ERCC2 rescues cisplatin sensitivity, the sensitivity profiles for S44L and S246F, identified in two cisplatin non-responders from the FCCC cohort, are similar to mock-infected cells. B. The S44L and S246F mutants also fail to rescue sensitivity to UV sensitivity. C. Immunoblot showing expression of FLAG-tagged WT or mutant ERCC2. Supplementary Figure 4: Identification of an ERCC2 E86Q mutation in matched pre- and post-treatment tumor samples. The E86Q mutation was not identified in the pre-treatment sample by the standard mutation-calling algorithm due to the low number of reads, but was later identified by "force-calling" after the E86Q mutation was identified in the post-treatment sample. Correcting for tumor purity, the E86Q mutation was inferred to be clonal in both the pre- and post-treatment samples. Supplementary Figure 5: Phylogenetic tree showing relationship between pre- and post-chemotherapy tumors from a patient with an ERCC2 E86Q mutation. The pre- and post-chemotherapy tumors share several mutations, indicating a common ancestor. Shared mutations in other select cancer genes are noted. Supplementary Figure 6: CRISPR/Cas9 technology was used to create a KU19-19 cell line harboring an in-frame deletion at the endogenous ERCC2 allele. A. An sgRNA guide was designed to target the region near T484, a common site of ERCC2 mutations in MIBC tumors. B. Integrated Genomics Viewer (IGV) screenshot showing sequence of WT ERCC2 allele in KU19-19 parental cell line. C. The CRISPR-edited cell line KE1 harbors an in-frame deletion at T484. Supplementary Figure 7: An ERCC2 mutation confers an NER defect in a bladder cancer cell line. Low magnification (20X) images from a DDB2 proteoprobe assay comparing KU19-19 (WT ERCC2) and KE1 (mutant ERCC2) cell lines (see Figure 4 for high magnification [63X] images). Whereas the KU19-19 cell line efficiently resolves DDB2 foci, the foci persist in NER-deficient KE1 cells. Supplementary Figure 8: KU19-19 (WT ERCC2) and KE1 (mutant ERCC2) cell lines have similar sensitivity to the PARP inhibitor olaparib. Supplementary Figure 9: Overall survival for patients with ERCC2 wild-type (blue) versus mutant (red) tumors in the updated TCGA bladder tumor cohort (Robertson et al. Cell 2017; 171:1-17). There was no significant difference in survival between the groups (P=0.095). This figure was created using cBioPortal (Gao et al. Sci Signaling 2013; 6(269):pl1 and Cerami et al. Cancer Discov 2012; 2(5):401).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Information from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Supplementary Figures and Methods // Supplementary Figure 1: The DDB2 proteo-probe assay measures cellular nucleotide excision repair (NER) capacity. Low magnification (20X) images of wild-type (WT) or mutant ERCC2-complemented XP cells before, 5 minutes after, and 150 minutes after UV exposure (see Figure 1 for high magnification [63X] images). DDB2 proteoprobe binding to UV-induced (6,4)-photoproducts is visualized using an anti-FLAG antibody (red). Nuclei are stained with DAPI (blue). ERCC2 expression is confirmed with an anti-Myc antibody (green). R683W is a common germline pathogenic allele, D312N is a common non-pathogenic germline allele, and G607A is a mutation identified in a cisplatin responsive tumor. Supplementary Figure 2: Sensitivity profiles for WT and mutant ERCC2-complemented cells for non-cisplatin agents. A. Carboplatin. B. Doxorubicin (Adriamycin) is a DNA intercalating agents that results in creation of double-strand DNA breaks. C. Rucaparib is a poly(ADP-ribose) polymerase inhibitor that demonstrates enhanced toxicity in homologous recombination (HR)-deficient cells. D. Ionizing radiation (IR). R683W is a common pathogenic germline allele in patients with the xeroderma pigmentosum complementation group D (XPD). D312N is a common, non-pathogenic germline ERCC2 allele in the general population. Y14C and G607A are helicase domain mutations identified in cisplatin responsive patients and are associated with NER loss and cisplatin sensitivity (Figure 2). Supplementary Figure 3: ERCC2 mutations identified in cisplatin non-responders are functionally deleterious. A. Cisplatin sensitivity curves for WT or mutant ERCC2-complemented cells. Whereas WT ERCC2 rescues cisplatin sensitivity, the sensitivity profiles for S44L and S246F, identified in two cisplatin non-responders from the FCCC cohort, are similar to mock-infected cells. B. The S44L and S246F mutants also fail to rescue sensitivity to UV sensitivity. C. Immunoblot showing expression of FLAG-tagged WT or mutant ERCC2. Supplementary Figure 4: Identification of an ERCC2 E86Q mutation in matched pre- and post-treatment tumor samples. The E86Q mutation was not identified in the pre-treatment sample by the standard mutation-calling algorithm due to the low number of reads, but was later identified by "force-calling" after the E86Q mutation was identified in the post-treatment sample. Correcting for tumor purity, the E86Q mutation was inferred to be clonal in both the pre- and post-treatment samples. Supplementary Figure 5: Phylogenetic tree showing relationship between pre- and post-chemotherapy tumors from a patient with an ERCC2 E86Q mutation. The pre- and post-chemotherapy tumors share several mutations, indicating a common ancestor. Shared mutations in other select cancer genes are noted. Supplementary Figure 6: CRISPR/Cas9 technology was used to create a KU19-19 cell line harboring an in-frame deletion at the endogenous ERCC2 allele. A. An sgRNA guide was designed to target the region near T484, a common site of ERCC2 mutations in MIBC tumors. B. Integrated Genomics Viewer (IGV) screenshot showing sequence of WT ERCC2 allele in KU19-19 parental cell line. C. The CRISPR-edited cell line KE1 harbors an in-frame deletion at T484. Supplementary Figure 7: An ERCC2 mutation confers an NER defect in a bladder cancer cell line. Low magnification (20X) images from a DDB2 proteoprobe assay comparing KU19-19 (WT ERCC2) and KE1 (mutant ERCC2) cell lines (see Figure 4 for high magnification [63X] images). Whereas the KU19-19 cell line efficiently resolves DDB2 foci, the foci persist in NER-deficient KE1 cells. Supplementary Figure 8: KU19-19 (WT ERCC2) and KE1 (mutant ERCC2) cell lines have similar sensitivity to the PARP inhibitor olaparib. Supplementary Figure 9: Overall survival for patients with ERCC2 wild-type (blue) versus mutant (red) tumors in the updated TCGA bladder tumor cohort (Robertson et al. Cell 2017; 171:1-17). There was no significant difference in survival between the groups (P=0.095). This figure was created using cBioPortal (Gao et al. Sci Signaling 2013; 6(269):pl1 and Cerami et al. Cancer Discov 2012; 2(5):401).